Siegfried to Acquire Small Molecules Drug Substance Capacity in the US
Siegfried signed binding agreements to acquire three drug substance sites in the US and Australia.
Small Molecules
Lilly Announces New $4.5 Billion Site
Eli Lilly and Company (Lilly) recently announced a $4.5 billion (€4.07 billion) investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development.
SK Pharmteco to Expand Production in South Korea
South Korean contract development and manufacturing organization (CDMO) SK Pharmteco announced a major expansion of its small molecule and peptide production capabilities with a $260 million investment to construct a new facility in Sejong, South Korea.
AbbVie to Build New Biologics Manufacturing Site in Singapore
Last week, AbbVie broke ground on a new Singapore manufacturing facility located in Singapore's Tuas Biomedical Park. The company will invest $223 million in the site which will add 24,000 l of biologics drug-substance capacity to AbbVie's global manufacturing network and support current products as well as emerging immunology and oncology compounds within its pipeline.
Integrated Drug Development Models
Interview with Giovanna Libralon, Senior Director Commercial Development Small Molecules at Lonza.
Managing Supply for Complex Biotherapeutics
Successfully managing the drug substance manufacturing of Antibody-Drug Conjugates (ADCs) requires a sophisticated understanding of the technological development process and access to a range of large- and small-molecule manufacturing assets.
Opportunities in Drug Development and Manufacturing
Growth in the global oncology drug market is an important measure of opportunities in drug development and manufacturing, including for contract manufacturers of active pharmaceutical ingredients (APIs) and finished drug products.
